efficacy and safety of a novel pegylated interferon alpha-2a in egyptian patients with genotype 4 chronic hepatitis c
Clicks: 184
ID: 251427
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
184 views
21 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #85 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and is the leading cause of liver disease.
| Reference Key |
taha2010canadianefficacy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Alaa Awad Taha;Ahmad El-Ray;Maged El-Ghannam;Bahaa Mounir |
| Journal | indian journal of pharmacology |
| Year | 2010 |
| DOI |
10.1155/2010/717845
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.